MA-SIMPLIVITY
SimpliVity, a leader in hyperconverged infrastructure for IT , announced today it has raised $175 million in series D funding at a valuation of more than $1 billion – a record achievement just 23 months after general availability of OmniCube, its flagship product. Waypoint Capital, the business enterprise for the Bertarelli family’s investments and headquartered in Geneva, Switzerland, led the round. Prior investors Accel Partners, Charles River Ventures, DFJ Growth, Kleiner Perkins Caufield & Byers (KPCB) and Meritech Capital Partners also contributed to the round. SimpliVity’s total venture funding is now $276 million.
Waypoint was inspired to make the investment after transforming its own IT environments across five global sites with SimpliVity’s hyperconverged infrastructure solution.
“As a customer, we experienced first-hand the transformational impact of SimpliVity’s hyperconverged infrastructure. After a thorough analysis of alternatives, we were convinced SimpliVity is technologically superior, and that its unique data architecture is years ahead of the market,” said Frederic Wohlwend, Chief Information and Technology Officer at Waypoint Capital. “When we learned SimpliVity was raising capital, we insisted on taking the lead. We see enormous potential in a company revolutionizing IT, and growing faster than any infrastructure company in recent history.”
“We are honored to have Waypoint join our extremely supportive group of investors. It is a unique and valuable opportunity to have an investor who is truly a customer first – with hands-on SimpliVity product experience,” said Doron Kempel, SimpliVity CEO. “The continued support from our existing investors is incredibly appreciated. Together, these investors give us the greatest strategic latitude for the business as we continue to optimize during this time of hyper growth.”
The financing will be used to fund the rapid expansion of the company and address the explosive market opportunity. Gartner predicts total integrated system spending will grow by a 24 percent CAGR from 2013 through 2018, reaching a total of $19 billion.
SimpliVity launched its hyperconverged infrastructure platform in April 2013 and delivered record growth in 2014. In 2014, SimpliVity grew revenues by more than 500 percent year over year; expanded with resellers into 50 countries and employees in 18; and grew its employee base to more than 400 worldwide. SimpliVity also partnered with Cisco in August 2014 in order to expand its global reach.
Morgan Stanley served as the sole placement agent for SimpliVity.
Supporting Quotes
“Legacy IT infrastructure is due for a shake-up and the market continues to show signs of acceleration,” said Mark Bowker, Senior Analyst, ESG. “There is significant interest in, and momentum behind hyperconverged infrastructure investments. Legacy architectures packaged and delivered with ‘a bow on top’ are failing to achieve the scale and operational efficiency we are seeing IT professionals achieve with a true hyperconverged platform like SimpliVity. This is the wave of the future and the path to modern IT infrastructure.”
“Accel Partners has not only invested in a company with a superior technology and enormous market opportunity, but in a leadership team that’s tuned to deliver,” said early investor and board member Kevin Comolli of Accel Partners. “This team has tremendous vision and one of the best abilities to execute that I’ve seen. SimpliVity has pioneered the hyperconverged infrastructure market and will emerge as a category leader. After just 23 months shipping product, the company has achieved an unprecedented sales trajectory.”
“When we first invested in SimpliVity, we saw a company that had the potential to transform how data is stored, managed and protected in the enterprise, which would truly impact one of the largest markets in technology,” said Bruce Sachs, General Partner, Charles River Ventures. “The growth of the customer base, product and management team has been very impressive and exceeded our expectations. SimpliVity has all of the right ingredients to lead in this market, and we are thrilled to be their business partners during this exciting time.”
“A $1+ billion valuation, and one of the largest rounds of venture capital ever for an enterprise company, are strong testaments to SimpliVity’s tremendous technology and massive addressable market,” said KPCB General Partner, Matt Murphy. “The product uptake and depth of penetration has been breathtaking: fully sixty-five percent of SimpliVity customers standardize all of their virtualized applications on SimpliVity’s platform.”
Additional Resources
- View the video and read the Waypoint case study
- Check out the microsite
- Learn more at SimpliVity’s blog
- Follow SimpliVity on Twitter , LinkedIn , Facebook , YouTube and Google+
About Waypoint
Waypoint Capital is a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family. The group is active in two areas: life sciences and asset management, including real estate. Chaired by Ernesto Bertarelli, Waypoint is headquartered in Geneva, with offices in London, Jersey, Boston and Luxembourg. Visit www.waypointcapital.net for more information.
About SimpliVity
Founded with a mission to simplify IT, SimpliVity is a pioneer in the hyperconverged infrastructure market, disrupting the status quo of complex and cumbersome legacy IT systems. SimpliVity’s hyperconverged IT platform delivers enterprise-class performance and availability that today’s IT leaders require, with the cloud economics their business demands. No other company has taken on the mega task of assimilating all IT elements below the hypervisor (8-12 disparate functions) into a simple 2U building block of x86 sharable resources to deliver unmatched IT simplicity, operational efficiency, and 3x TCO savings. The company’s unique data virtualization architecture improves performance, protection and data efficiency, while also enabling global unified management from a single console. SimpliVity has revolutionized IT systems for hundreds of enterprises around the world. Headquartered in Westborough, Mass., the company has raised more than $276 million in venture capital and employs more than 400 worldwide. SimpliVity's business model is 100 percent indirect, and its solutions and professional services are available worldwide through its network of resellers and distributors. For more information, visit www.simplivity.com .
Note: SimpliVity, the SimpliVity logo, OmniCube, OmniStack, and Data Virtualization Platform are trademarks or registered trademarks of SimpliVity Corporation in the United States and certain other countries. All trademarks and registered trademarks mentioned herein belong to their respective owners.
Contact:
SimpliVity Media Contacts
North
America
SimpliVity
Melissa Mahoney, 508-720-8227
Vice
President, Communications
melissa.mahoney@simplivity.com
or
Version
2.0 Communications
Katelyn Holbrook, 617-426-2222
kholbrook@v2comms.com
or
EMEA
Axicom
Robin
Wolstenholme, +44 (0)208 3924079
robin.wolstenholme@axicom.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum